Article

Prevalence of cardiovascular risk factors in patients with psoriasis

Dermatology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
Journal of the American Academy of Dermatology (Impact Factor: 5). 12/2006; 55(5):829-35. DOI: 10.1016/j.jaad.2006.08.040
Source: PubMed

ABSTRACT Previous studies suggest that patients hospitalized for psoriasis have an increased frequency of a variety of cardiovascular comorbidities. Limited population-based data exist on this association, and few studies have determined which factors are independently associated with psoriasis.
We sought to determine whether the prevalence of the major cardiovascular risk factors was higher in mild and severe psoriasis than in patients without psoriasis.
We conducted a population-based study in the United Kingdom using the General Practice Research Database. Patients were classified as having severe psoriasis if they received a code for psoriasis as well as systemic therapy. Patients were defined as having mild psoriasis if they ever received a psoriasis code but no systemic therapy. Control subjects were selected from the same practices and start dates as psoriasis patients. Patients were classified as having risk factors if they received codes for diabetes, hypertension, hyperlipidemia, obesity, or smoking. Analyses were performed by using conditional logistic regression, and adjustments were made considering age, gender, person-years, and all cardiovascular risk factors.
We identified 127,706 patients with mild psoriasis and 3854 with severe psoriasis. Respective prevalence rates of risk factors in those with severe psoriasis, mild psoriasis, and in controls were as follows: diabetes (7.1%, 4.4%, 3.3%), hypertension (20%, 14.7%, 11.9%), hyperlipidemia (6%, 4.7%, 3.3%), obesity (20.7%, 15.8%, 13.2%), and smoking (30.1%, 28%, 21.3%). Patients with mild psoriasis had a higher adjusted odds of diabetes (odds ratio [OR], 1.13; 95% confidence interval [CI], 1.08-1.18]), hypertension (OR, 1.03; 95% CI, 1.01-1.06), hyperlipidemia (OR, 1.16; 95% CI, 1.12-1.21), obesity (OR, 1.27; 95% CI, 1.24-1.31), and smoking (OR, 1.31; 95% CI, 1.29-1.34) than controls. Patients with severe psoriasis had a higher adjusted odds of diabetes (OR, 1.62; 95% CI, 1.3-2.01), obesity (OR, 1.79; 95% CI, 1.55-2.05), and smoking (OR, 1.31; 95% CI, 1.17-1.47) than controls. Additionally, diabetes (OR, 1.39; 95% CI, 1.22-1.58) and obesity (OR, 1.47; 95% CI, 1.32-1.63) were more prevalent in those with severe psoriasis than with mild psoriasis.
The study was cross-sectional and therefore the directionality of the associations could not be determined.
Multiple cardiovascular risk factors are associated with psoriasis. Cardiovascular risk factors that are key components of the metabolic syndrome are more strongly associated with severe psoriasis than with mild psoriasis.

Download full-text

Full-text

Available from: Andrea B Troxel, Jan 06, 2014
0 Followers
 · 
155 Views
    • "Based on the localisation and symptoms, the disease is classified into different types (Griffiths et al. 2007). Plaque psoriasis is the most prevalent leading to complications like increased cardiovascular risk (Neimann et al. 2006), cancer, Crohn's disease and psoriatic arthritis (Traub & Marshall 2007). Prolonged use of allopathic medications/phototherapy causes side effects like nausea, ulceration, itching of the skin, squamous cell carcinoma etc. (Winterfield et al. 2005). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Andrographis nallamalayana is being widely used as tribal medicine in the treatment of leucoderma and mouth ulcers. Chemical profiling of methanolic extract of the whole plant (PE), using GC-MS and LC-MS, revealed the presence of compounds viz. α-tocopherol, β-sitosterol, tetradecanoic acid, monostearin, flavones/flavanones and their glycosides, chromones, etc. Topical application of imiquimod on the dorsal portion of male BALB/C mice resulted in the development of psoriatic symptoms (erythema, scaling, thickening and folding) with a mean disease activity index (DAI) of >7.0. Topical treatment with 100-μL PE (~6.4%/12.8%) formulations, for 12-days, resulted in the alleviation of disease symptoms. Compared to water-based formulations, emu oil-based formulation, PE400EO was found more effective in reducing the mean DAI (>84%), keratinocyte count (>65%) (p < 0.01) and interleukin-22 (~70%) (p < 0.05). We report, for the first time, anti-psoriatic activity of A. nallamalayana having great potential in developing a potent phytomedicine against psoriasis.
    Natural product research 07/2015; DOI:10.1080/14786419.2015.1054825 · 1.23 Impact Factor
  • Source
    • "Suprabasal CK1 expression was confirmed in all normal skin, psoriasis, chronic eczema and lichen planus samples (Fig. 1). As Nnat is involved in insulin secretion [6,7] and psoriasis is associated with metabolic syndrome [12] [13], we compared the immunostaining intensity of Nnat among patients with or without metabolic syndrome, but no apparent difference was noted. We next examined the expression of Nnat, Inv, and CK1 in cultured NHEKs by performing immunofluorescence staining. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Neuronatin (Nnat), which is a neuronal developmental and differentiation molecule, is expressed in the endoplasmic reticulum of non-neuronal cells and is involved in insulin secretion from pancreatic β-cells by plausibly modulating their intracellular calcium concentration. However, the role of Nnat in keratinocyte differentiation remains unclear. To unveil a possible integration of Nnat in controlling the keratinocyte differentiation markers such as involucrin, cytokeratin1, filaggrin, loricrin and S100A7. Immunohistological staining was done using psoriasis, chronic eczema, lichen planus and normal skin. Immunofluorescence staining, Western blotting and semi-quantitative real-time PCR were performed for detecting Nnat, involucrin, cytokeratin1, filaggrin, loricrin and S100A7 using human keratinocytes with or without Nnat gene transfection. Small interference RNA was applied to knockdown the Nnat gene expression. Nnat existed in normal human epidermis and cultured keratinocytes. In the hyperplastic epidermis of psoriasis, chronic eczema and lichen planus, over-expression of Nnat was evident along with involucrin and cytokeratin1 expression. Coordinate up-regulation of Nnat and involucrin, but not cytokeratin1, was demonstrated in cultured keratinocytes under differentiation stimuli such as extracellular calcium elevation, exposure to phorbol myristate acetate, and increased cell density. Transfection of small intereference RNA for Nnat decreased the mRNA levels of Nnat and involucrin, but not of cytokeratin1. Furthermore, a gene transfection assay showed increased involucrin expression in the Nnat-transfected keratinocytes than in mock-transfected counterparts, without any appreciable influence on cytokeratin1, filaggrin, loricrin and S100A7 expression. These data indicate that Nnat is related to keratinocyte differentiation by up-regulating involucrin expression.
    Journal of dermatological science 10/2013; DOI:10.1016/j.jdermsci.2013.10.008 · 3.34 Impact Factor
  • Source
    • "Chronic plaque-type psoriasis is a chronic inflammatory skin disorder that affects approximately 2 percent of the world's population and is associated with obesity in 13– 34% of cases [1] [2]. The relative risk of psoriasis has been reported to be directly related to body mass index (BMI), and positive correlation between psoriasis severity and BMI has been established [3]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background. Chronic plaque psoriasis is frequently associated with obesity. The effect of a low-calorie diet on psoriasis has not been investigated. Objective. The objective was to investigate whether moderate weight loss increases the therapeutic response to topical treatment in obese patients with chronic stable plaque-type psoriasis. Material and Method. A 24-week clinical trial was conducted in 10 patients. The efficacy of a low-calorie diet with topical treatment was compared with baseline in obese patients with chronic stable plaque-type psoriasis. The primary measure of clinical response was the Psoriasis Area and Severity Index at weeks 12 and 24. Results. At week 12, the mean reduction in body weight was 9.6 percent. There was an improvement from baseline of 50 percent or more in the Psoriasis Area and Severity Index in 50 percent of the patients. The responses as measured by improvements in the Psoriasis Area and Severity Index were paralleled by improvements in global assessments by the physician and the patients and in the Dermatology Life Quality Index. Conclusion. Obese patients with chronic stable plaque-type psoriasis increase their response to a low-calorie diet. Lifestyle modifications, including a low-calorie diet, may supplement the pharmacologic treatment of obese psoriasis patients.
    Dermatology Research and Practice 09/2013; 2013:795932. DOI:10.1155/2013/795932
Show more